

COVID-19's Impact on Autoimmune Brands

The current public health pandemic is impacting healthcare stakeholders from doctors and nurses in the frontlines to payers and PBMs. EVERSANA™ is monitoring the constant changes to access and benefit consideration tracking payer responses and key trends that may impact Autoimmune brands.

According to recent research released by Health Strategies Insights by EVERSANA™, the management of autoimmune and other non-life-threatening diseases have taken a back seat to COVID-19 and other related specialties like pulmonology and infectious disease.

Autoimmune therapies are currently being utilized to treat COVID-19 patients. This has already caused supply challenges that will impact future utilization and prescribing patterns, with select providers already switching current autoimmune patients off of these high-in-demand drugs.

“

The day to day attention is on COVID-19 and anything related to it, like infections, bacterial infections, pneumonia, etc.

– Health System Pharmacy

”

“


It's already changed a lot for us, we're having supply chain issues...autoimmune patients are being shifted to other avenues of care (self-admin), and we're saving the drugs for COVID19 patients.

– Health System Pharmacy

”

To ensure continuity of care to autoimmune patients on office-administered therapies, health plans have taken numerous measures to guarantee proper management and care during the pandemic. These efforts typically include supporting physicians to provide safe and seamless administration of office-administered therapies by lessening administrative tasks (e.g., prior authorizations, reauthorizations etc.)


Plan Action to Support Autoimmune Patients on Office-Administered Drugs During COVID-19
(Percentage plans)



N=40 health plans. Source: Health Strategies Insights by EVERSANA, Multiple Sclerosis Brand Access Marketplace Dynamics, May 2020.

The COVID-19 pandemic had limited impact on contracting negotiations with biopharmaceutical companies. After the initial shift in business practices, payers have continued as “business as usual”, but virtually. While many payers will eventually go back to some face-to-face meetings, many will continue to meet virtually with biopharmaceutical companies, making it increasingly important that contracting discussions, supporting materials and overall logistics are supportive of this avenue.

“
I think (future) face-to-face meetings will be the exception versus the rule.
– Blues Medical”



Source: Health Strategies Insights by EVERSANA, COVID-19 Payer Pulse, May 2020.

To learn more about Health Strategies Insights by EVERSANA™, visit eversana.com/products/health-strategies-insights.



About EVERSANA™

EVERSANA is the leading independent provider of global services to the life science industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product lifecycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit EVERSANA.COM or connect through [LinkedIn](#) and [Twitter](#).

